



Washington State Health Care Authority
Prescription Drug Program
P.O. Box 91132 • Seattle, Washington 98111-9232
206-521-2027 • FAX 206-521-2001 • TTY 360-923-2701 • www.rx.wa.gov

May 11, 2009

Dear Interested Party,

Following recommendations by the Washington State Pharmacy and Therapeutics Committee, the Department of Social and Health Services - Health and Recovery Services Administration (DSHS-HRSA), the Health Care Authority – Public Employees Health Plans (PEHP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL).

Each agency will use the common PDL according to its benefit structure. The agencies will implement these changes **effective July 1, 2009**.

Combination Asthma Products Drug Class

fluticasone/salmeterol (Advair Diskus[®], Advair HFA[®])
budesonide/formoterol (Symbicort[®])

(EFFECT: adds a new drug class to the Washington PDL)

Leukotriene Modifiers

Decision delayed pending P&T clarification of its April 15, 2009 motion (Agenda item for the June 17, 2009 P&T meeting)

Long-Acting Beta Agonist Drug Class

formoterol (Foradil[®])
salmeterol (Serevent Diskus[®])

(EFFECT: no change to the current PDL)

Inhaled Corticosteroids Drug Class

flunisolide (Aerobid[®], Aerobid-M[®])
triamcinolone (Azmacort[®])
fluticasone (Flovent HFA[®], Flovent Diskus[®])
budesonide (Pulmicort Respules[®], Pulmicort Flexhaler[®])
beclomethasone (Qvar[®])

(EFFECT: removes mometasone furoate (Asmanex[®]) from the current PDL)

Statin Drug Class


lovastatin *
pravastatin*
rosuvastatin (Crestor®)
simvastatin *

*generic products only

Not covered by L&I
(EFFECT: no change to the current PDL)

If you have other questions or comments regarding this announcement, please contact Regina Chacon at (206) 521-2027 or by email at pdp@hca.wa.gov.

Sincerely,



Duane Thurman
Director, Prescription Drug Programs
Washington State Health Care Authority